Open Access Letter to the Editor

Clinical pathways for inborn errors of metabolism: warranted and feasible

Serwet Demirdas1, Imke N van Kessel1, Marjolein J Korndewal1, Carla EM Hollak2, Hanka Meutgeert3, Anja Klaren3, Margreet van Rijn4, Francjan J van Spronsen4, Annet M Bosch1* and Dutch working Group

Author Affiliations

1 Department of Pediatrics, Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

2 Department of Internal Medicine, Division of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

3 The Dutch Society for Adults and Children with an Inborn Error of Metabolism (VKS), Zwolle, The Netherlands

4 Division of Metabolic Diseases, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

For all author emails, please log on.

Orphanet Journal of Rare Diseases 2013, 8:37  doi:10.1186/1750-1172-8-37

Published: 25 February 2013

Abstract

Inborn errors of metabolism (IEMs) are known for their low prevalence and multidisciplinary care mostly founded on expert opinion. Clinical pathways are multidisciplinary tools to organise care which provide a clear route to the best care and improve communication. In 2010 the Dutch Society for Children and Adults with an Inborn Error of Metabolism (VKS) initiated development of clinical pathways for inborn errors of metabolism. In this letter to the editor we describe why it is warranted to develop clinical pathways for IEMs and shortly discuss the process of development for these pathways in the Netherlands.

Keywords:
Phenylketonuria; PKU; Clinical pathway